Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences
Restricted accessResearch articleFirst published online August, 2022
Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences
Psychedelics are able to acutely alter emotional reactivity and self-consciousness. However, whether the regular naturalistic use of psychedelics can be linked to more persistent trait-level changes in these domains remains an open question.
Aim:
To test the hypotheses that (1) using psychedelics is related to higher positive and lower negative emotional reactivity; and (2) an adaptive pattern of self-consciousness, including diminished public self-consciousness and rumination, and increased reflection and self-awareness; and (3) these relations are mediated by the intensity of past ego-dissolution and mystical experiences.
Method:
An online survey including questions about the history of psychoactive substance use; questionnaires measuring trait levels of emotional reactivity and self-consciousness; questionnaires for retrospective assessment of ego-dissolution and mystical experiences. Data collected from 2516 participants (1661 psychedelics users) were analyzed using robust linear regression and mediation analysis.
Results:
A higher number of lifetime uses of psychedelics predicted greater positive and lower negative emotional reactivity; also, in the domain of self-consciousness, it predicted greater reflection and internal state awareness, and reduced rumination tendency and public self-consciousness. Finally, the intensity of past mystical and ego-dissolution experiences mediated almost all the observed relationships between the lifetime number of psychedelics uses and psychological variables.
Conclusions:
Lifetime psychedelics use predicts an adaptive pattern of trait-level emotional reactivity and self-consciousness. Ego-dissolution and mystical experiences are essential in understanding the long-lasting psychological effects of psychedelics use. Our findings might potentially explain previous observations of increased well-being in psychedelics users.
AdayJSMitzkovitzCMBloeschEK, et al. (2020) Long-term effects of psychedelic drugs: A systematic review. Neuroscience and Biobehavioral Reviews113: 179–189.
2.
Agin-LiebesGIMaloneTYalchMM, et al. (2020) Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology34(2): 155–166.
3.
AndersonEMBohonLMBerriganLP (1996) Factor structure of the Private Self-Consciousness Scale. Journal of Personality Assessment66(1): 144–152.
AnthonyFVHermansCAMSterkensC (2010) A comparative study of mystical experience among Christian, Muslim, and Hindu students in Tamil Nadu, India. Journal for the Scientific Study of Religion49(2): 264–277.
6.
BecerraRPreeceDCampitelliG, et al. (2017) The assessment of emotional reactivity across negative and positive emotions: Development and validation of the Perth Emotional Reactivity Scale (PERS). Assessment26(5): 867–879.
7.
BousoJCDos SantosRGAlcázar-CórcolesMÁ, et al. (2018) Serotonergic psychedelics and personality: A systematic review of contemporary research. Neuroscience & Biobehavioral Reviews87: 118–132.
8.
BousoJCGonzálezDFondevilaS, et al. (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: A longitudinal study. PLoS ONE7(8): e42421.
9.
BurnkrantREPageTJ (1984) A modification of the Fenigstein, Scheier and Buss Self-Consciousness Scale. Journal of Personality Assessment48(6): 629–637.
10.
CarbonaroTMBradstreetMPBarrettFS, et al. (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology (Oxford, England)30(12): 1268–1278.
11.
Carhart-HarrisRGiribaldiBWattsR, et al. (2021) Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine384(15): 1402–1411.
12.
Carhart-HarrisRLNuttDJ (2010) User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. Journal of Substance Use15(4): 283–300.
13.
Carhart-HarrisRLBolstridgeMRuckerJ, et al. (2016) Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry3(7): 619–627.
14.
Carhart-HarrisRLErritzoeDWilliamsT, et al. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America109(6): 2138–2143.
15.
Carhart-HarrisRLRosemanLBolstridgeM, et al. (2017) Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. Scientific Reports7(1): 1–11.
16.
Carhart-HarrisRLRosemanLHaijenE, et al. (2018) Psychedelics and the essential importance of context. Journal of Psychopharmacology (Oxford, England)32(7): 725–731.
CreedATFunderDC (1998) The two faces of private self-consciousness: Self report, peer-report, and behavioral correlates. European Journal of Personality12(6): 411–431.
19.
DaSilveiraADeSouzaMLGomesWB (2015) Self-consciousness concept and assessment in self-report measures. Frontiers in Psychology6: 930.
20.
DavisAKBarrettFSMayDG, et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry78(5): 481–489.
21.
DolderPCSchmidYMüllerF, et al. (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology41(11): 2638–2646.
22.
ErritzoeDRosemanLNourMM, et al. (2018) Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica138(5): 368–378.
23.
FenigsteinAScheierMFBussAH (1975) Public and private self-consciousness: Assessment and theory. Journal of Consulting and Clinical Psychology43(4): 522–527.
24.
FranquesaASainz-CortAGandyS, et al. (2018) Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach. Psychiatry Research264: 334–339.
25.
Galvão-CoelhoNLMarxWGonzalezM, et al. (2021) Classic serotonergic psychedelics for mood and depressive symptoms: A meta-analysis of mood disorder patients and healthy participants. Psychopharmacology238(2): 341–354.
26.
Garcia-RomeuAGriffithsRRJohnsonMW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews7(3): 157–164.
27.
GriffithsRRJohnsonMWRichardsWA, et al. (2011) Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl)218: 649–665.
28.
GriffithsRRJohnsonMWRichardsandWA, et al. (2018) Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology32(1): 49–69.
29.
GriffithsRRJohnsonMWCarducciMA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology (Oxford, England)30(12): 1181–1197.
30.
GriffithsRRRichardsWAMcCannU, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology187(3): 268–292.
31.
GriffithsRRRichardsWJohnsonM, et al. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology (Oxford, England)22(6): 621–632.
32.
HaijenECHMKaelenMRosemanL, et al. (2018) Predicting responses to psychedelics: A prospective study. Frontiers in Pharmacology9: 897.
HayesAFPreacherKJ (2014) Statistical mediation analysis with a multicategorical independent variable. The British Journal of Mathematical and Statistical Psychology67(3): 451–470.
35.
HendricksPSJohnsonMWGriffithsRR (2015a) Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology29(9): 1041–1043.
36.
HendricksPSThorneCBClarkCB, et al. (2015b) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology29(3): 280–288.
37.
HendricksPS (2018) Awe: A putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. International Review of Psychiatry (Abingdon, England)30(4): 331–342.
38.
HoffmanA (1968) Psychotomimetic agents. In: BurgerA (ed.) Drugs Affecting the Central Nervous System, vol. 2. New York: M. Dekker, p.169.
39.
JohansenP-ØKrebsTS (2015) Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology29(3): 270–279.
40.
KettnerHMasonNLKuypersKPC (2019) Motives for classical and novel psychoactive substances use in psychedelic polydrug users. Contemporary Drug Problems46: 304–320.
41.
KlimkiewiczAJakubczykAMachA, et al. (2021) Psychometric properties of the Polishpolish version of the Alcohol Use Disorders Identification Test (AUDIT). Drug and Alcohol Dependence218: 108427.
42.
KollerMStahelWA (2017) Nonsingular subsampling for regression S estimators with categorical predictors. Computational Statistics32(2): 631–646.
43.
KometerMSchmidtABachmannR, et al. (2012) Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biological Psychiatry72(11): 898–906.
44.
KraehenmannRPrellerKHScheideggerM, et al. (2015) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological Psychiatry78(8): 572–581.
45.
KrebsTSJohansenPØ (2013) Psychedelics and mental health: A population study. PLoS ONE8(8): e63972.
46.
LafranceAStrahanEBirdBM, et al. (2021) Classic psychedelic use and mechanisms of mental health: Exploring the mediating roles of spirituality and emotion processing on symptoms of anxiety, depressed mood, and disordered eating in a community sample. Journal of Humanistic Psychology. Epub ahead of print 9October. DOI: 10.1177/00221678211048049.
47.
LawnWHallakJECrippaJA, et al. (2017) Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: A large, international, self-selecting online survey. Scientific Reports7(1): 1–10.
48.
LebedevAVKaelenMLövdénM, et al. (2016) LSD-induced entropic brain activity predicts subsequent personality change. Human Brain Mapping37(9): 3203–3213.
49.
LernerMLyversM (2006) Values and beliefs of psychedelic drug users: A cross-cultural study. Journal of Psychoactive Drugs38(2): 143–147.
50.
LethebyCGerransP (2017) Self unbound: Ego dissolution in psychedelic experience. Neuroscience of Consciousness2017(1): 1–11.
51.
LuomaJBChwylCBathjeGJ, et al. (2020) A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. Journal of Psychoactive Drugs52(4): 289–299.
52.
LyversMMeesterM (2012) Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Journal of Psychoactive Drugs44(5): 410–417.
53.
MacLeanKAJohnsonMWGriffithsRR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology25(11): 1453–1461.
MasonNLKuypersKPC (2018) Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics. Journal of Psychedelic Studies2: 45–52.
56.
Nolen-HoeksemaSWiscoBELyubomirskyS (2008) Rethinking rumination. Perspectives on Psychological Science: A Journal of the Association for Psychological Science3(5): 400–424.
57.
NourMMEvansLNuttD, et al. (2016) Ego-dissolution and psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience10: 269.
58.
OlsonDE (2021) The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science4: 563–567.
59.
Palhano-FontesFAndradeKCTofoliLF, et al. (2015) The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS ONE10(2): e0118143.
60.
Palhano-FontesFBarretoDOniasH, et al. (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine49(4): 655–663.
61.
PreeceDBecerraRCampitelliG (2019) Assessing emotional reactivity: Psychometric properties of the Perth Emotional Reactivity Scale and the development of a short form. Journal of Personality Assessment101(6): 589–597.
62.
PrellerKHVollenweiderFX (2018) Phenomenology, structure, and dynamic of psychedelic states. In: HalberstadtALVollenweiderFXNicholsDE (eds) Behavioral Neurobiology of Psychedelic Drugs. Berlin; Heidelberg: Springer Berlin Heidelberg, pp.221–256.
63.
R Core Team (2018) R: A Language and Environment for Statistical Computing. Available at: http://www.r-project.org/
RadońS (2014b) Psychometric properties of the Polishpolish version of mystical experience. Studia Psychologica14: 59–76.
66.
RochaJMOsórioFLCrippaJAS, et al. (2019) Serotonergic hallucinogens and recognition of facial emotion expressions: A systematic review of the literature. Therapeutic Advances in Psychopharmacology9: 2045125319845774.
67.
RosemanLHaijenEIdialu-IkatoK, et al. (2019) Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. Journal of Psychopharmacology33(9): 1076–1087.
68.
RosemanLNuttDJCarhart-HarrisRL (2017) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology8: 974.
69.
RossSBossisAGussJ, et al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology (Oxford, England)30(12): 1165–1180.
70.
RyanRMKuczkowskiR (1994) The imaginary audience, self-consciousness, and public individuation in adolescence. Journal of Personality62(2): 219–238.
71.
SampedroFde la Fuente RevengaMValleM, et al. (2017) Assessing the psychedelic “after-glow” in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. International Journal of Neuropsychopharmacology20(9): 698–711.
72.
SchmidtSAkrofiKCarpenter-ThompsonJR, et al. (2013) Default mode, dorsal attention and auditory resting state networks exhibit differential functional connectivity in tinnitus and hearing loss. PLoS ONE8(10): 1–12.
73.
SeaboldSPerktoldJ (2010) Statsmodels: Econometric and statistical modeling with Python. In: Proceedings of the 9th python in science conference, Austin, Texas, pp.57–61.
74.
SextonJDNicholsCDHendricksPS (2019) Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Frontiers in Psychiatry / Frontiers Research Foundation10: 896.
75.
SmigielskiLKometerMScheideggerM, et al. (2020) P300-mediated modulations in self–other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self–other overlap. Human Brain Mapping41(17): 4982–4996.
76.
SmigielskiLScheideggerMKometerM, et al. (2019) Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage196: 207–215.
77.
TagliazucchiERosemanLKaelenM, et al. (2016) Increased global functional connectivity correlates with LSD-induced ego dissolution. Current Biology: CB26(8): 1043–1050.
78.
ThiessenMSWalshZBirdBM, et al. (2018) Psychedelic use and intimate partner violence: The role of emotion regulation. Journal of Psychopharmacology32(7): 749–755.
79.
TimmermannCKettnerHLethebyC, et al. (2021) Psychedelics alter metaphysical beliefs. Scientific Reports11(1): 1–13.
80.
TrapnellPDCampbellJD (1999) Private self-consciousness and the five-factor model of personality: Distinguishing rumination from reflection. Journal of Personality and Social Psychology76(2): 284–304.
81.
UthaugMVDavisAKHaasTF, et al. (2022) The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology36: 309–320.
82.
UthaugMVLancelottaRvan OorsouwK, et al. (2019) A single inhalation of vapor from dried toad secretion containing 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology236(9): 2653–2666.
83.
UthaugMVvan OorsouwKKuypersKPC, et al. (2018) Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology235(10): 2979–2989.
84.
Van MulukomVPattersonREvan ElkM (2020) Broadening your mind to include others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism. Psychopharmacology237(9): 2725–2737.
85.
VollenweiderFXPrellerKH (2020) Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nature Reviews. Neuroscience21(11): 611–624.
86.
WatsonPJMorrisRJRamseyA, et al. (1996) Further contrasts between self-reflectiveness and internal state awareness factors of private self-consciousness. The Journal of Psychology130(2): 183–192.
87.
World Health Organization (2001) AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care (ed BaborTFHiggins-BiddleJCSaundersJB, et al.). 2nd ed.World Health Organization.
88.
YadenDBGriffithsRR (2021) The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science4(2): 568–572.
89.
YadenDBNguyenKDLe KernML, et al. (2017) Of roots and fruits: A comparison of psychedelic and nonpsychedelic mystical experiences. Journal of Humanistic Psychology57(4): 338–353.
90.
ZakrzewskiJStrzałkowskaA (1989) Dyspozycyjna koncentracja na sobie: teoria i pomiar. In: DrwalRŁ (ed.) Techniki Kwestionariuszowe W Diagnostyce Psychologicznej. Wybrane Zagadnienia. Lublin: Wydawnictwo UMCS, pp.189–210.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
